BiotechTube

Tetrabenazine

ApprovedUNKNOWN
0 watching 0 views this week🔥 Hot
82
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease

Trial Timeline

Aug 1, 2018 → Jul 1, 2023

NCT ID
NCT02509793

About Tetrabenazine

Tetrabenazine is a approved stage product being developed by Lundbeck for Huntington's Disease. The current trial status is unknown. This product is registered under clinical trial identifier NCT02509793. Target conditions include Huntington's Disease.

Hype Score Breakdown

Clinical
30
Activity
20
Company
7
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT02509793ApprovedUNKNOWN

Competing Products

15 competing products in Huntington's Disease

See all competitors
ProductCompanyStageHype Score
AFQ056 + PlaceboNovartisPhase 2
52
RO7234292 (RG6042)RochePhase 2
52
RG6496 + PlaceboRochePhase 1
33
PF-02545920 + PF-02545920PfizerPhase 2
51
20 mg BID of PF-02545920PfizerPhase 2
51
PF-02545920 + Placebo + PF-02545920 + PlaceboPfizerPhase 2
51
ALN-HTT02 + PlaceboAlnylam PharmaceuticalsPhase 1
30
BN82451B + PlaceboIpsenPhase 2
49
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mgIonis PharmaceuticalsPhase 1/2
38
WVE-120102 + PlaceboWaVe Life SciencesPhase 1/2
36
WVE-120101 + PlaceboWaVe Life SciencesPhase 1/2
36
SAGE-718Supernus PharmaceuticalsPhase 3
72
SAGE-718 + PlaceboSupernus PharmaceuticalsPhase 2
47
OMS643762 + PlaceboOmeros CorporationPhase 2
47
VX15/2503 + PlaceboVaccinexPhase 2
44

Other Products from Lundbeck

VortioxetineApproved
82
memantine + memantine + placeboApproved
82
escitalopram + escitalopramApproved
82
BrexpiprazoleApproved
82
losartan (drug)Approved
82